

## THC Form 7

### MONTHLY PROGRESS REPORT

September

Name of CSE Issuer           **THC Biomed Intl Ltd.**  
Trading Symbol:               **THC**  
Number of Outstanding  
Listed Securities               **152,867,404 common shares and 48,818,697 reserved  
for Issuance**  
Date:                               **October 7, 2019**

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**On September 9, 2019 the Company announced that Health Canada had completed an inspection at its flagship Acland road facility.**

**“This inspection brings us a step closer to supplying adult Canadian Cannabis users with an alternative, brand-new product THC Kiss,” commented John Miller, CEO of THC.**

**“We believe licensed producers need to be more innovative and invent their own brand of new products. These products need to be better than products currently available on the grey market, rather than copying and trying to compete with current illicit market products.”**

**THC Kiss is a new, innovative Cannabis beverage invented by THC.**

**THC Kiss, when approved, will only be available through authorized provincial distributors as well as registered patients.**

**On September 17, 2019 the Company announced that it has submitted a new product application to Health Canada for THC BioMed's Pure Cannabis Sticks. Pure Cannabis Sticks are filtered, paper cylinders filled with pure THC BioMed cannabis.**

**Pure Cannabis Sticks are to be manufactured using THC BioMed's automated production machine. They are to be packaged in lots of 3 and 20. Each Pure Cannabis Stick is intended for a single-use session and has a biodegradable filter.**

**The filters are natural, rapidly degrading and commercial-quality, made using raw materials that include flax, cotton, and manila hemp, with no artificial compounds. The purpose of the filters is convenience only. A filter is there to stop loose cannabis from going into a user's mouth.**

**“We look forward to the approval of our Pure Cannabis Sticks,” commented John Miller, CEO of THC Biomed, “The introduction of these automated cannabis pre-rolled cylinders would make a significant change in the cannabis industry.”**

**If the Pure Cannabis Sticks are approved by Health Canada, THC BioMed (www.thcbiomed.com) intends to discuss co-manufacturing agreements with larger Licensed Producers, some of whom have already expressed an interest to THC. If these co-manufacturing agreements are realized, THC would manufacture pre-rolls on behalf of other Licensed Producers.**

**“We see great potential in Pure Cannabis Sticks. We expect them to provide a new and significant revenue stream for our company,” Miller said, “We believe that licensed producers need to be more innovative and invent their own brands of new products that are better than what is available on the gray market, rather than copying and competing with current gray market products.”**

**If the Pure Cannabis Sticks are approved by Health Canada, THC Biomed would be the first Canadian licensed cannabis producer to distribute Pure Cannabis Sticks.**

Provide a general overview and discussion of the activities of management.

**None**

2. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**None.**

3. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**None.**

4. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**None.**

5. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**None.**

6. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**None.**

7. Describe the acquisition of new customers or loss of customers.

**The Issuer has continued to register new patients.**

8. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

9. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

**None, except in the ordinary course of business.**

10. Report on any labour disputes and resolutions of those disputes if applicable.

**None.**

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**None.**

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

The Company closed a non-brokered private placement of convertible debentures for gross proceeds of \$642,679.09 (the "Debenture"). Dated August 16, 2019, the term of the Debenture is 12 months and bears interest at 8% per annum calculated on an annual basis and payable semi-annually in arrears. The Debenture is convertible into common shares at a price of \$0.25 per share, at any time at the election of the holder.

The proceeds of the Debenture will be used by the Company towards funding the continuous growth and expansion of the Company as well as general working capital

**None.**

13. Provide details of any securities issued and options or warrants granted.

14. Provide details of any loans to or by Related Persons.

**None.**

15. Provide details of any changes in directors, officers or committee members.

**None.**

16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**The Issuer's business involves certain risks and uncertainties that are inherent to the Company's industry. For disclosure on risks related to an investment in the Issuer, please refer to the Company's most recent Management's Discussion and Analysis under the titles "Financial Instruments and Risk Management" and "Other Risks and Uncertainties", which is available on SEDAR at [www.sedar.com](http://www.sedar.com).**

#### **Certificate of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

**Dated: October 7, 2019.**

**John Miller**

Name of Director or Senior Officer

*"John Miller"*

Signature

**President and CEO**  
 Official Capacity

<b>Issuer Details</b>		
Name of Issuer: <b>THC Biomed Intl Ltd.</b>	For Month End September	Date of Report: YYYYMMDD <b>2019/10/07</b>
Issuer Address: <b>P.O. Box 20033 Towne Centre</b>		
City/Province/Postal Code: <b>Kelowna, BC V1Y 9H2</b>	Issuer Fax No.: <b>N/A</b>	Issuer Telephone No. <b>(250) 870-2512</b>
Contact Name: <b>John Miller</b>	Contact Position: <b>President &amp; CEO</b>	Contact Telephone No. <b>(250) 870-2512</b>
Contact Email Address: <b>info@thcbiomed.com</b>	Web Site Address: <b>www.thcbiomed.com</b>	